Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Gaig, Carles ^a,b,c   Vilas, Dolores ^a   Infante, Jon ^c,d   Sierra, María ^c,d   García Gorostiaga, Inés ^e   Buongiorno, Mariateresa ^a,b   Ezquerra, Mario ^a,b,c   Martí, Maria José ^a,b,c   Valldeoriola, Francesc ^a,b,c   Aguilar, Miquel ^f   Calopa, Matilde ^f   Hernandez Vara, Jorge ^g   Tolosa, Eduardo ^a,b,c  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL DE GALDAKAO   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ANXIETY; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GENE; GENETIC ASSOCIATION; HALLUCINATION; HUMAN; HYPOSMIA; LRRK2 GENE; MALE; PARKINSON DISEASE; PARKINSONISM; PREVALENCE; PROSPECTIVE STUDY; PSYCHOSIS; SEX DIFFERENCE; SLEEP DISORDER; SYMPTOMATOLOGY; URINARY DYSFUNCTION; CASE CONTROL STUDY; COMPLICATION; GENETICS; MIDDLE AGED; MISSENSE MUTATION; OLFACTION DISORDERS; SLEEP DISORDERS;

LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

AGED; CASE-CONTROL STUDIES; CONSTIPATION; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; OLFACTION DISORDERS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SEX FACTORS; SLEEP DISORDERS;

EID: 84908042711     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108982     Document Type: Article

References (36)

1. Paisán Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44(4): 595-600.
2. Gilks WP, Abou Sleiman PM, Gandhi S, Jain S, Singleton A, et al. (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365: 415-6.
3. Gaig C, Ezquerra M, Marti MJ, Munoz E, Valldeoriola F, et al. (2006) LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 63: 377-82.
4. Goldwurm S, Zini M, Di Fonzo A, De Gaspari D, Siri C, et al. (2006) LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord 12: 410-9.
5. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7: 583-90.
6. Silveira Moriyama L, Guedes LC, Kingsbury A, Ayling H, Shaw K, et al. (2008) Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data. Neurology 71: 1021-6.
7. Simuni T, Sethi K (2008) Nonmotor manifestations of Parkinson's disease. Ann Neurol 64: S65-80.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-4.
9. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, et al. (2007) Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22: 1689-707.
10. Möller JC, Körner Y, Dodel RC, Meindorfner C, Stiasny Kolster K, et al. (2005) Pharmacotherapy of Parkinson's disease in Germany. J Neurol 252: 926-35.
11. Doty RL, Bromley SM, Stern MB (1995) Olfactory testing as an aid in the diagnosis of Parkinson's disease: development of optimal discrimination criteria. Neurodegeneration 4: 93-7.
12. Doty RL, Shaman P, Applebaum SL, Giberson R, Siksorski L, et al. (1984) Smell identification ability: changes with age. Science 226: 1441-3.
13. Washington (1994) American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV.
14. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67: 361-70.
15. Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, et al. (2007) Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 22: 1061-8.
16. Friedberg G, Zoldan J, Weizman A, Melamed E (1998) Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 21: 280-4.
17. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, et al. (2006) Functional bowel disorders. Gastroenterology 130: 1480-91.
18. Riegler G, Esposito I (2001) Bristol scale stool form. A still valid help in medical practice and clinical research. Tech Coloproctol 5: 163-4.
19. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ (2004) Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord 19: 1306-12.
20. Medicine AASM (2005) International Classification of Sleep Disorders- Second Edition.
21. Gjerstad MD, Aarsland D, Larsen JP (2002) Development of daytime somnolence over time in Parkinson's disease. Neurology 58: 1544-6.
22. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28: 193-213.
23. Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14: 540-5.
24. Chaudhuri KR, Pal S, DiMarco A, Whately Smith C, Bridgman K, et al. (2002) The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 73: 629-35.
25. Khan NL, Katzenschlager R, Watt H, Bhatia KP, Wood NW, et al. (2004) Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 62: 1224-6.
26. Hayashi S, Wakabayashi K, Ishikawa A, Nagai H, Saito M, et al. (2000) An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 15: 884-8.
27. Poulopoulos M, Levy OA, Alcalay RN (2012) The neuropathology of genetic Parkinson's disease. Mov Disord 27: 831-42.
28. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J (2004) Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 75: 637-9.
29. Orr Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, et al. (2007) The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology 69: 1595-602.
30. Kasten M, Kertelge L, Brüggemann N, van der Vegt J, Schmidt A, et al. (2010) Nonmotor symptoms in genetic Parkinson disease. Arch Neurol 67: 670-6.
31. Marras C, Schüle B, Munhoz RP, Rogaeva E, Langston JW, et al. (2011) Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 77: 325-33.
32. Iranzo A, Santamaria J, Tolosa E (2009) The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases. Sleep Med Rev 13: 385-401.
33. Ruiz Martínez J, Gorostidi A, Goyenechea E, Alzualde A, Poza JJ, et al. (2011) Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations. Mov Disord 26: 2026-31.
34. Saunders Pullman R, Stanley K, Wang C, San Luciano M, Shanker V, et al. (2011) Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology 77: 319-24.
35. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
36. Brockmann K, Gröger A, Di Santo A, Liepelt I, Schulte C, et al. (2011) Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 26: 2335-42.